Hikari Tsushin Inc. trimmed its holdings in shares of AbbVie Inc. (NYSE:ABBV – Free Report) by 18.1% during the third quarter, HoldingsChannel reports. The fund owned 83,101 shares of the company’s stock after selling 18,342 shares during the quarter. AbbVie comprises 1.5% of Hikari Tsushin Inc.’s holdings, making the stock its 9th largest position. Hikari Tsushin Inc.’s holdings in AbbVie were worth $21,738,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. Financial Freedom LLC acquired a new position in shares of AbbVie during the third quarter worth $29,000. Burk Holdings LLC acquired a new stake in AbbVie in the second quarter valued at $30,000. Marquette Asset Management LLC increased its holdings in AbbVie by 52.2% in the second quarter. Marquette Asset Management LLC now owns 140 shares of the company’s stock valued at $35,000 after purchasing an additional 48 shares during the period. Principia Wealth Advisory LLC increased its holdings in AbbVie by 38.9% in the second quarter. Principia Wealth Advisory LLC now owns 157 shares of the company’s stock valued at $40,000 after purchasing an additional 44 shares during the period. Finally, IMG Wealth Management Inc. raised its position in AbbVie by 3,060.0% during the 2nd quarter. IMG Wealth Management Inc. now owns 158 shares of the company’s stock worth $40,000 after purchasing an additional 153 shares during the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about AbbVie
Investors following ABBV have been watching these headlines:
- Positive Sentiment: Piper Sandler raised its price target to $349 from $303 and maintained an Overweight rating, implying about 23% upside from the prior close. Article: AbbVie Is Near Its High. Piper Sandler Sees Another 23%
- Positive Sentiment: AbbVie partnered with DISCO Pharmaceuticals to discover next-generation bispecific cancer therapies for solid tumors. DISCO could receive up to $2.5 billion in milestone payments, while AbbVie has options to license selected programs; the deal adds pipeline potential, though returns depend on successful research and development. Article: DISCO, AbbVie Sign AND-Gated Bispecific Deal Worth Up to $2.5B
- Neutral Sentiment: AbbVie will present at the Piper Sandler healthcare conference on December 2; the announcement may provide an opportunity for updates but includes no new business guidance. Article: AbbVie to Present at the Piper Sandler 38th Annual Healthcare Conference
Insider Buying and Selling at AbbVie
In other news, EVP Jeffrey Stewart sold 40,619 shares of AbbVie stock in a transaction dated Monday, November 9th. The stock was sold at an average price of $293.60, for a total value of $11,925,738.40. Following the completion of the transaction, the executive vice president directly owned 83,171 shares of the company’s stock, valued at approximately $24,419,005.60. This trade represents a 32.81% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Company insiders own 0.06% of the company’s stock.
Wall Street Analyst Weigh In
Several research analysts have commented on ABBV shares. Scotiabank lifted their target price on AbbVie from $280.00 to $320.00 and gave the stock an “outperform” rating in a report on Tuesday, October 6th. Royal Bank Of Canada upped their price target on AbbVie from $280.00 to $330.00 and gave the company an “outperform” rating in a research report on Monday, November 2nd. Leerink Partners increased their price target on AbbVie from $309.00 to $342.00 and gave the company an “outperform” rating in a research note on Monday, November 2nd. Canaccord Genuity Group raised their price objective on AbbVie from $290.00 to $338.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. Finally, The Goldman Sachs Group lifted their price objective on AbbVie from $258.00 to $294.00 and gave the stock a “neutral” rating in a research note on Friday, October 23rd. One research analyst has rated the stock with a Strong Buy rating, twenty-two have issued a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $299.62.
View Our Latest Stock Report on ABBV
AbbVie Stock Performance
NYSE:ABBV opened at $286.19 on Friday. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $302.93. The firm’s fifty day moving average is $278.98 and its 200-day moving average is $242.55. The firm has a market cap of $505.88 billion, a P/E ratio of 49.26, a P/E/G ratio of 1.34 and a beta of 0.20.
AbbVie (NYSE:ABBV – Get Free Report) last announced its earnings results on Friday, October 30th. The company reported $3.82 earnings per share for the quarter, topping analysts’ consensus estimates of $3.73 by $0.09. The business had revenue of $17.40 billion during the quarter, compared to the consensus estimate of $17.32 billion. AbbVie had a net margin of 15.67% and a negative return on equity of 450.55%. AbbVie’s quarterly revenue was up 10.3% on a year-over-year basis. During the same quarter last year, the firm earned $1.86 earnings per share. As a group, sell-side analysts anticipate that AbbVie Inc. will post 13.99 earnings per share for the current year.
AbbVie Increases Dividend
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, February 16th. Shareholders of record on Friday, January 15th will be issued a dividend of $1.82 per share. This represents a $7.28 dividend on an annualized basis and a yield of 2.5%. The ex-dividend date is Friday, January 15th. This is an increase from AbbVie’s previous quarterly dividend of $1.73. AbbVie’s dividend payout ratio (DPR) is 119.10%.
About AbbVie
AbbVie is a biopharmaceutical company that discovers, develops and markets medicines for a range of serious health conditions. Its research and product portfolio spans immunology, oncology, neuroscience and other therapeutic areas. Key products include the immunology medicines Skyrizi and Rinvoq, cancer treatments such as Imbruvica and Venclexta, and neuroscience therapies including Botox and Vraylar. Through its Allergan acquisition, AbbVie also offers aesthetics products such as Botox Cosmetic and Juvéderm.
Featured Stories
- Five stocks we like better than AbbVie
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
- MarketBeat Week in Review – 11/16 – 11/20
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
Want to see what other hedge funds are holding ABBV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AbbVie Inc. (NYSE:ABBV – Free Report).
Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.
